OBJECTIVE: In multiple myeloma (MM), seven primary recurrent translocations involving the immunoglobulin heavy chain locus have been identified. One of the partner loci maps to 20q12 and involves the MAFB gene resulting in its ectopic expression. We attempt here to identify MAFB target genes in MM. MATERIALS AND METHODS: We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20). Microarray expression analysis was used to detect gene expression changes upon MAFB expression. These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene. Functional implications of these upregulated genes were studied by testing their promoter activity in reporter assays. C-MAF was included comparatively as well. RESULTS: The inducible cell lines identified a total of 284 modulated transcripts. After further evaluation using ex vivo data 14 common upregulated genes were found, common to the C-MAF pathway as well. The promoter activity of some of these secondary genes proved a functional relationship with MAFB. In connection with one of these secondary genes (NOTCH2), even tertiary upregulated genes were found. Functional studies indicated that inducible MAFB expression conferred antiapoptotic effects. CONCLUSION: We identified 14 upregulated genes, and their downstream consequences in the combined MAFB/C-MAF pathway. Eleven of these genes are novel in the C-MAF pathway as well. These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.
OBJECTIVE: In multiple myeloma (MM), seven primary recurrent translocations involving the immunoglobulin heavy chain locus have been identified. One of the partner loci maps to 20q12 and involves the MAFB gene resulting in its ectopic expression. We attempt here to identify MAFB target genes in MM. MATERIALS AND METHODS: We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20). Microarray expression analysis was used to detect gene expression changes upon MAFB expression. These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene. Functional implications of these upregulated genes were studied by testing their promoter activity in reporter assays. C-MAF was included comparatively as well. RESULTS: The inducible cell lines identified a total of 284 modulated transcripts. After further evaluation using ex vivo data 14 common upregulated genes were found, common to the C-MAF pathway as well. The promoter activity of some of these secondary genes proved a functional relationship with MAFB. In connection with one of these secondary genes (NOTCH2), even tertiary upregulated genes were found. Functional studies indicated that inducible MAFB expression conferred antiapoptotic effects. CONCLUSION: We identified 14 upregulated genes, and their downstream consequences in the combined MAFB/C-MAF pathway. Eleven of these genes are novel in the C-MAF pathway as well. These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.
Authors: Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini Journal: Cell Date: 2009-05-14 Impact factor: 41.582
Authors: Gary Lu; Ramya Muddasani; Robert Z Orlowski; Lynne V Abruzzo; Muzaffar H Qazilbash; M James You; Yaping Wang; Ming Zhao; Su Chen; Isabella Claudia Glitza; L Jeffrey Medeiros Journal: Arch Pathol Lab Med Date: 2013-05 Impact factor: 5.534
Authors: Y Hu; H Su; C Liu; Z Wang; L Huang; Q Wang; S Liu; S Chen; J Zhou; P Li; Z Chen; H Liu; G Qing Journal: Oncogene Date: 2016-09-05 Impact factor: 9.867
Authors: Paola Neri; Li Ren; Abdel Kareem Azab; Matthew Brentnall; Kathy Gratton; Alexander C Klimowicz; Charles Lin; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Lawrence H Boise; Irene M Ghobrial; Nizar J Bahlis Journal: Blood Date: 2011-04-07 Impact factor: 22.113
Authors: Alexandra Pisklakova; Eileen Grigson; Maria Ozerova; Feng Chen; Daniel M Sullivan; Yulia Nefedova Journal: Cancer Biol Ther Date: 2016-03-02 Impact factor: 4.742